Oric Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
240 E Grand Ave Fl 2, South San Francisc...Phone Number
(650) 388-5600Website
www.oricpharma.comRevenue
$114.1 MillionStock Symbol
ORICIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance. ORIC's lead program, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to treatment resistance to multiple classes of anti-cancer therapeutics across a variety of solid tumors. ORIC's pipeline also includes an orally bioavailable small molecule inhibitor of CD73, as well as other undisclosed programs targeting mechanisms of oncology therapeutic resistance. ORIC is funded by biotechnology investors and is headquartered in South San Francisco, California.Explore more
Oric Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oric Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Oric Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Oric Pharmaceuticals
Product Launch: Get notified when Oric Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Oric Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Oric Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Oric Pharmaceuticals recently announced quarterly report
Click to see if Oric Pharmaceuticals had a recent Job posting/layoffs
Check if Oric Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Oric Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Oric Pharmaceuticals
Compare insights from companies similar to Oric Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Oric Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Oric Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Oric Pharmaceuticals.
Oric Pharmaceuticals financials insights
Gather financial insights about Oric Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$15M
2015
Series B
$53M
2018
Series C
$50M
2019
Series D
$55M
2023
Share Placement
$85M
2025
Stock/Share Issuance
$125M
Oric Pharmaceuticals Tech Stack
A closer look at the technologies used by Oric Pharmaceuticals
See more technologies
Most Recent Scoops
Open Position
Person-Based
Events
Person-Based
Open Position
Open Position
Oric Pharmaceuticals News & Media
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateroneORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO and SAN DIEGO, July 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2026 (the “Grant Date”), ORIC granted a total of 44,400 non-qualified stock options and 7,200 restricted stock units to three new non-executive employees who began their employment with ORIC in June 2026.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in June:
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oric Pharmaceuticals
Sign Up For FreeTo access detailed company insights
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance. ORIC's lead program, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to treatment resistance to multiple classes of anti-can... Read More
